Delving into the Latest Updates on Burroughs Wellcome with Synapse

概览

疾病领域	数量

感染	1
神经系统疾病	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

DNA-directed DNA polymerase(DNA-指导DNA聚合酶)	1

关联

5

项与 Burroughs Wellcome 相关的药物

Acyclovir

阿昔洛韦

靶点

DNA-directed DNA polymerase

作用机制

DNA-指导DNA聚合酶抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

英国

首次获批日期1981-01-01

BW-373U86

靶点

δ opioid receptor x σ1 receptor

作用机制

δ opioid receptor激动剂 [+1]

在研机构-

原研机构

Burroughs Wellcome

在研适应症-

非在研适应症

抑郁症 [+1]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

BW-424C79

靶点-

作用机制-

在研机构-

原研机构

Burroughs Wellcome

在研适应症-

非在研适应症

疼痛

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

100 项与 Burroughs Wellcome 相关的临床结果

登录后查看更多信息

0 项与 Burroughs Wellcome 相关的专利（医药）

登录后查看更多信息

8

项与 Burroughs Wellcome 相关的文献（医药）

1996-03-01·Chest1区 · 医学

A Placebo-Controlled Trial of Prostacyclin in Acute Respiratory Failure in COPD

1区 · 医学

Article

作者: Stephen L. Archer ; James Crow ; Debra Mike ; Edward K Weir ; Walker Long

Although patients with COPD often have elevated pulmonary artery pressures (PAP) and pulmonary vascular resistance (PVR), it is uncertain whether treatment of this pulmonary hypertension is beneficial. We evaluated the extent of pulmonary hypertension in 16 patients with severe COPD complicated by acute respiratory failure and pulmonary hypertension. We assessed the hypothesis that the vasodilator prostacyclin (PGI2) would reduce PVR and improve systemic O2 transport. Patients with a COPD exacerbation requiring mechanical ventilation, and mean PAP greater than 30 mm Hg, were randomized to receive PGI2 or placebo, in addition to conventional therapy. Randomization to PGI2 or placebo therapy occurred 1 to 12 h after intubation, while the patient was mechanically ventilated. An optimal PGI2 dose (2 to 12 ng/kg/min, IV) was established in an initial dose-ranging study and then this dose was infused continuously for 48 h. PGI2 initially reduced PVR, but this effect dissipated within 24 h, indicating the development of tachyphylaxis. Tolerance to the adverse effects of PGI2 (tachycardia, hypotension, flushing, and headache) also developed over time. PGI2 treatment was associated with a significant fall in PaO2 but no increase in systemic oxygen transport. PGI2 proved to be a nonselective vasodilator that caused mild hypoxemia. Despite acute respiratory failure, pulmonary hypertension is mild in patients with severe COPD receiving mechanical ventilation and IV PGI2 is not beneficial in such patients.

1993-09-01·Journal of Cardiovascular Pharmacology4区 · 医学

Terfenadine Alters Action Potentials in Isolated Canine Purkinje Fibers More Than Acrivastine

4区 · 医学

Article

作者: Lang, Daniel G. ; Wenger, Thomas L. ; Wang, Ching M.

Acrivastine and terfenadine are second-generation antihistamines with similar pharmacologic profiles and comparable clinical efficacies for allergic rhinitis. However, terfenadine therapy has been associated with cardiovascular side effects that include prolonged QT interval, torsades de pointes, and ventricular fibrillation (VF). We examined the adverse effects induced by terfenadine on evoked action potentials (APs) in isolated canine cardiac Purkinje fibers and determined whether acrivastine causes similar disturbances in this preparation. Terfenadine produced a statistically significant decrease in the maximal rate of increase in the AP (dV/dt) at 10(-7) M, which corresponds to the highest plasma concentration observed clinically. The IC50 (mean +/- SEM) value for terfenadine-induced inhibition of dV/dt was 1.3 +/- 0.3 x 10(-6) M. The decrease in dV/dt caused by terfenadine became more pronounced with faster rates of stimulation. Acrivastine at a concentration of 10(-5) M, a value 10 times higher than plasma concentrations observed in clinical studies, caused no significant changes in AP duration (APD) or dV/dt. The IC50 (mean +/- SEM) value for the acrivastine-induced inhibition of dV/dt was estimated to be 8.0 +/- 3.7 x 10(-3) M. Terfenadine blocked the evoked AP at 3 x 10(-6) M, whereas no block was observed with acrivastine at 10(-3) M. The effective serum concentration of acrivastine is approximately 100 times higher than that of terfenadine. Because the IC50 value for inhibition of dV/dt for acrivastine is approximately 6,000 times greater than that for terfenadine, we estimate that acrivastine is approximately 60-fold less likely to cause disturbances in cardiac conduction than terfenadine.

1985-01-01·Prostaglandins, Leukotrienes, and Lipoxins

Different Functions of Phosphoinositide Turnover and Arachidonate Metabolism for Platelet Activation

作者: Wolfgang Siess ; Peter C. Weber ; Eduardo G. Lapetina

In a wide variety of cells including platelets, the hormone-induced breakdown of phosphoinositides by phospholipase C is closely associated with the mobilization of Ca2+ from intracellular stores (Michell, 1975). Recent studies gave new insights into the possible link between phosphoinositide breakdown and intracellular Ca2+mobilization: myoinositol-l,4,5-trisphosphate, the phosphodiesteratic cleavage product of phosphatidylinositol-4,5-biphosphate, mobilizes Ca2+ from the endoplasmatic reticulum in pancreatic acinar cells and hepatocytes (Streb et al., 1983; Joseph et al.,1984). Besides myoinositol-1,4,5-trisphosphate, two other products of the phos-pholipase-C-induced degradation of the phosphoinositides have possible functions as intracellular activators: 1,2-diacylglycerol activates the Ca2+, phospholipid-dependent protein kinase C, and phosphatidic acid has been implicated in Ca2+fluxes and membrane fusion processes (Nishizuka, 1983; Sundler and Papahadjo-poulos, 1981; Fig. 1).

100 项与 Burroughs Wellcome 相关的药物交易

登录后查看更多信息

100 项与 Burroughs Wellcome 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年02月18日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

1

4

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

阿昔洛韦 ( DNA-directed DNA polymerase )	单纯疱疹更多	批准上市
BW-424C79	疼痛更多	终止
BW-373U86 ( δ opioid receptor x σ1 receptor )	未指明的药物依赖更多	终止
BW-1205U90 ( 5-HT1A receptor x 5-HT2 receptor x A1R )	精神障碍更多	无进展
BW-2258-U89 ( Bombesin receptor )	小细胞肺癌更多	无进展